Nitroglycerin Lingualnitroglycerin

According to the FDA label: 1 INDICATIONS & USAGE Nitroglycerin Lingual Spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

39,140 adverse event reports submitted to the FDA (1999–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Nitroglycerin Lingual in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Nitroglycerin Lingual adverse event reports by reporter sex
SexReports
Male19,056
Female17,161
Unknown33

By Age Group

View age group data as a table
Nitroglycerin Lingual adverse event reports by reporter age group
Age groupReports
0-17185
18-34386
35-491,989
50-647,882
65-747,674
75+9,882

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Nitroglycerin Lingual. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Nitroglycerin Lingual adverse event reports by reported outcome
OutcomeReports
Other Serious20,398
Hospitalization18,706
Non-Serious7,157
Death5,278
Life-Threatening2,416
Disability1,300

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Nitroglycerin Lingual. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Nitroglycerin Lingual adverse event reports by year
YearReports
19991
20021
20032
2004948
20051,062
2006897
2007676
2008899
20091,199
20101,365
20112,237
20121,664
2013816
20142,366
20151,410
20161,612
20171,691
20182,073
20192,238
20202,090
20212,220
20222,850
20232,840
20242,789
20252,661
2026 (partial)533

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Nitroglycerin Lingual

In FDA adverse event reports that mention Nitroglycerin Lingual, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026